CAS: 1000787-75-6

Tegobuvir

Tegobuvir (GS 333126) is a specific and covalent HCV NS5B polymerase inhibitor.

5-((6-(2,4-Bis(Trifluoromethyl)Phenyl)Pyridazin-3-Yl)Methyl)-2-(2-Fluorophenyl)-5H-Imidazo[4,5-C]Pyridine

Tegobuvir is a drug that inhibits the NS3 protease protein of the hepatitis C virus (HCV). It has been shown to be effective against HCV genotype 1b and 3a, which are the two most prevalent HCV genotypes in the world. The mechanism of action of tegobuvir is to inhibit viral replication by binding to the NS3 protease. Tegobuvir has been shown to be effective against both wild-type and resistance-associated substitutions. Tegobuvir has been shown to have pharmacokinetic properties that allow it to be taken orally. This drug can also be used as a starting point for repositioning, which is when a drug with known efficacy in one disease state is used for other diseases. Tegobuvir has been found to block sofosbuvir, an inhibitor of HCV NS5B polymerase, in vitro. Tegobuvir may also have antiviral activity against HIV-1 by